Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

被引：0

作者：

Nakagawa, K. ^{[1
]}

Nagasaka, M. ^{[2
]}

Felip, E. ^{[3
,4
]}

Pacheco, J. ^{[5
]}

Baik, C. ^{[6
]}

Goto, Y. ^{[7
]}

Saltos, A. ^{[8
]}

Li, B. ^{[9
]}

Udagawa, H. ^{[10
]}

Gadgeel, S. ^{[11
]}

Murakami, H. ^{[12
]}

Planchard, D. ^{[13
]}

Bazhenova, L. ^{[14
]}

Paz-Ares, L. ^{[15
,16
]}

Perol, M. ^{[17
]}

Mazieres, J. ^{[18
,19
]}

Barlesi, F. ^{[20
]}

Saxena, K. ^{[21
]}

Shiga, R. ^{[21
]}

Acharyya, S. ^{[21
]}

Cheng, Y. ^{[21
]}

Shahidi, J. ^{[21
]}

Janne, P. ^{[22
,23
]}

Smit, E. ^{[24
]}

机构：

[1] Kindai Univ Hosp, Osaka, Japan

[2] Karmanos Canc Inst, Detroit, MI USA

[3] Vall DHebron Univ Hosp, Barcelona, Spain

[4] Vall DHebron Inst Oncol, Barcelona, Spain

[5] Univ Colorado, Aurora, CO USA

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Natl Canc Ctr, Tokyo, Japan

[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[10] Natl Canc Ctr Hosp East, Chiba, Japan

[11] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA

[12] Shizuoka Canc Ctr, Shizuoka, Japan

[13] Gustave Roussy, Thorac Team, Villejuif, France

[14] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA

[15] Univ Complutense, Spanish Natl Canc Res Ctr, Hosp Univ 12 Octubre, Madrid, Spain

[16] Ciberonc, Madrid, Spain

[17] Ctr Leon Berard, Lyon, France

[18] Toulouse Univ Hosp, Toulouse, France

[19] Paul Sabatier Univ, Toulouse, France

[20] Aix Marseille Univ, CNRS, INSERM, Crcm,AP HP, Marseille, France

[21] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[22] Dana Farber Canc Inst, Boston, MA 02115 USA

[23] Belfer Ctr Appl Canc Sci, Boston, MA USA

[24] Netherlands Canc Inst, Amsterdam, Netherlands

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

HER2-expressing; Trastuzumab deruxtecan; Metastatic non-small cell lung cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA04.05

引用

页码：S109 / S110

页数：2

共 50 条

[1] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
Smit, E.
Nakagawa, K.
Nagasaka, M.
Felip, E.
Goto, Y.
Li, B.
Pacheco, J.
Murakami, H.
Barlesi, F.
Saltos, A.
Perol, M.
Udagawa, H.
Saxena, K.
Shiga, R.
Guevara, F.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S173
[2] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
Smit, E. F.
Felip, E.
Uprety, D.
Nakagawa, K.
Paz-Ares, L.
Pacheco, J.
Li, B. T.
Planchard, D.
Baik, C.
Goto, Y.
Murakami, H.
Saltos, A.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Feng, W.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
[3] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Smit, Egbert F.
Felip, Enriqueta
Uprety, Dipesh
Nagasaka, Misako
Nakagawa, Kazuhiko
Rodriguez, Luis Paz-Ares
Pacheco, Jose M.
Li, Bob T.
Planchard, David
Baik, Christina
Goto, Yasushi
Murakami, Haruyasu
Saltos, Andreas
Pereira, Kaline
Taguchi, Ayumi
Cheng, Yingkai
Yan, Qi
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
[J]. LANCET ONCOLOGY, 2024, 25 (04): : 439 - 454
[4] DESTINY-Lung01 Trial Investigators Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Sharayah, Ahmad
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (06) : 749 - 750
[5] Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
Smit, Egbert F.
[J]. FUTURE ONCOLOGY, 2024,
[6] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
Janne, P.
Goto, Y.
Kubo, T.
Ninomiya, K.
Kim, S. -W.
Planchard, D.
Ahn, M. -J.
Smit, E. F.
de Langen, A. J.
Perol, M.
Pons-Tostivint, E.
Novello, S.
Hayashi, H.
Shimizu, J.
Kim, D. -W.
Pereira, K.
Cheng, F. -C.
Taguchi, A.
Cheng, Y.
Goto, K.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
[7] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Smit, Egbert F.
Nakagawa, Kazuhiko
Nagasaka, Misako
Felip, Enriqueta
Goto, Yasushi
Li, Bob T.
Pacheco, Jose Maria
Murakami, Haruyasu
Barlesi, Fabrice
Saltos, Andreas Nicholas
Perol, Maurice
Udagawa, Hibiki
Saxena, Kapil
Shiga, Ryota
Guevara, Ferdinand M.
Acharyya, Suddhasatta
Shahidi, Javad
Planchard, David
Janne, Pasi A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Li, B. T.
Smit, E. F.
Goto, Y.
Nakagawa, K.
Goto, K.
Mazieres, J.
Uprety, D.
Bazhenova, L.
Saltos, A.
Felip, E.
Pacheco, J.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Planchard, D.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S995 - S996
[9] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Li, B. T.
Smit, E. F. F.
Goto, Y.
Nakagawa, K.
Udagawa, H.
Mazieres, J.
Nagasaka, M.
Bazhenova, L.
Saltos, A. N.
Felip, E.
Pacheco, J. M.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
[10] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
Khatri, Amit
Cobbina, Enoch
Cheng, Shen
Abutarif, Malaz
Garimella, Tushar
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →